Income Statement (TTM)
Inhibrx Biosciences, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | -0 | 2 | 2 | 2 | 2 | 0 | 0 | 1 |
| Change (%) | -61.06 | -154.30 | -747.48 | -0.94 | 3.93 | -6.42 | -88.47 | 0.00 | 600.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 102 | 112 | 118 | 192 | 158 | 154 | 154 | 204 | 201 | 173 |
| Change (%) | 9.83 | 6.01 | 62.00 | -17.32 | -3.08 | 0.54 | 31.96 | -1.44 | -13.76 | |
| % of Revenue | 7,726.46 | 21,794.63 | -42,551.80 | 10,646.67 | 8,886.48 | 8,287.10 | 8,904.04 | 101,871.50 | 100,403.50 | 12,369.21 |
| Gross Operating Profit | -100 | -111 | -119 | -190 | -157 | -152 | -153 | -204 | -201 | -172 |
| Change (%) | 10.76 | 6.75 | 60.11 | -17.48 | -3.16 | 0.63 | 33.33 | -1.44 | -14.38 | |
| % of Revenue | -7,626.46 | -21,694.63 | 42,651.80 | -10,546.67 | -8,786.48 | -8,187.10 | -8,804.04 | -101,771.50 | -100,303.50 | -12,269.21 |
| SG&A | 15 | 16 | 18 | 29 | 33 | 119 | 119 | 60 | 56 | -31 |
| Change (%) | 7.79 | 12.57 | 60.87 | 12.19 | 261.54 | 0.01 | -49.73 | -6.60 | -155.55 | |
| % of Revenue | 1,143.35 | 3,165.14 | -6,561.87 | 1,630.28 | 1,846.44 | 6,423.37 | 6,865.05 | 29,922.00 | 27,947.00 | -2,217.86 |
| R&D | 60 | 98 | 98 | -24 | -42 | |||||
| Change (%) | 64.39 | 0.00 | 73.75 | |||||||
| % of Revenue | 3,345.99 | 5,292.55 | 5,655.77 | -12,019.00 | -2,983.21 | |||||
| OpEx | 117 | 128 | 137 | 221 | 251 | 371 | 372 | 264 | 233 | 100 |
| Change (%) | 9.56 | 6.84 | 61.85 | 13.59 | 47.66 | 0.23 | -29.05 | -11.73 | -56.87 | |
| % of Revenue | 8,869.81 | 24,959.77 | -49,113.67 | 12,276.94 | 14,078.91 | 20,003.02 | 21,424.86 | 131,793.50 | 116,331.50 | 7,168.14 |
| Operating Income | -115 | -127 | -137 | -219 | -249 | -369 | -370 | -263 | -232 | -99 |
| Change (%) | 10.37 | 7.49 | 60.21 | 13.71 | 47.97 | 0.26 | -28.77 | -11.74 | -57.43 | |
| % of Revenue | -8,769.81 | -24,859.77 | 49,213.67 | -12,176.94 | -13,978.91 | -19,903.02 | -21,324.86 | -131,693.50 | -116,231.50 | -7,068.14 |
| Interest Expense | -8 | -15 | -32 | -32 | -30 | -22 | -13 | -8 | -6 | |
| Change (%) | 104.52 | 105.84 | 1.78 | -7.85 | -27.29 | -37.87 | -40.33 | -27.58 | ||
| % of Revenue | -1,477.15 | 5,564.03 | -1,768.89 | -1,817.55 | -1,611.60 | -1,252.25 | -6,745.50 | -4,025.00 | -416.43 | |
| Net Income | -115 | -130 | -142 | -241 | -271 | 1,634 | 1,642 | 1,688 | 1,723 | -164 |
| Change (%) | 12.51 | 9.68 | 69.61 | 12.34 | -702.57 | 0.49 | 2.79 | 2.10 | -109.50 | |
| % of Revenue | -8,769.96 | -25,341.41 | 51,189.57 | -13,408.94 | -15,207.80 | 88,176.36 | 94,684.72 | 843,786.00 | 861,485.50 | -11,692.43 |
Source: Capital IQ
